AZN in “GLP-1 Eats Everything”
AstraZeneca PLC
AstraZeneca is building an obesity franchise around oral GLP-1 candidate AZD5004 and complementary cardiometabolic therapies.
AZN impact map — “GLP-1 Eats Everything”
How this story travels from the headline to AZN’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading AZN impact map…
Price history, marked with story events
Aug 25, 2025 – Aug 26, 2026 · 253 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — AstraZeneca is building an obesity franchise around oral GLP-1 candidate AZD5004 and complementary cardiometabolic therapies.
Read the full GLP-1 Eats Everything story